OTCMKTS:CLVLY

Clinuvel Pharmaceuticals Stock Forecast, Price & News

$23.20
+0.01 (+0.04 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$22.81
Now: $23.20
$23.32
50-Day Range
$16.95
MA: $20.75
$23.35
52-Week Range
$12.68
Now: $23.20
$23.49
Volume9,203 shs
Average Volume7,111 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CLVLY
CUSIPN/A
CIKN/A
Phone61 3 9660 4900
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1059th out of 2,018 stocks

Biotechnology Industry

46th out of 147 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$23.20
+0.01 (+0.04 %)
(As of 04/20/2021 05:19 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLVLY News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVLY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Frequently Asked Questions

Is Clinuvel Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clinuvel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Clinuvel Pharmaceuticals stock.
View analyst ratings for Clinuvel Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Clinuvel Pharmaceuticals?

Wall Street analysts have given Clinuvel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clinuvel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals saw a drop in short interest in March. As of March 31st, there was short interest totaling 2,000 shares, a drop of 42.9% from the March 15th total of 3,500 shares. Based on an average trading volume of 11,000 shares, the short-interest ratio is presently 0.2 days.
View Clinuvel Pharmaceuticals' Short Interest
.

Who are Clinuvel Pharmaceuticals' key executives?

Clinuvel Pharmaceuticals' management team includes the following people:
  • Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D., CEO, MD & Director (Age 58, Pay $1.32M)
  • Mr. Darren M. Keamy, CFO & Company Sec. (Age 48, Pay $284.08k)
  • Dr. Dennis J. Wright, Chief Scientific Officer
  • Mr. Malcolm Bull, Head of Investor Relations
  • Lachlan Hay, Gen. Mang. of Europe

Who are some of Clinuvel Pharmaceuticals' key competitors?

What is Clinuvel Pharmaceuticals' stock symbol?

Clinuvel Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CLVLY."

How do I buy shares of Clinuvel Pharmaceuticals?

Shares of CLVLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clinuvel Pharmaceuticals' stock price today?

One share of CLVLY stock can currently be purchased for approximately $23.20.

What is Clinuvel Pharmaceuticals' official website?

The official website for Clinuvel Pharmaceuticals is www.clinuvel.com.

How can I contact Clinuvel Pharmaceuticals?

The company can be reached via phone at 61 3 9660 4900.


This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.